NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Cancer

• Publication date

  2018-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.31057PMID 28921505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

  2016cited by this paper
• Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling

  2016cited by this paper
• NFAT-1, Sp-1, Sp-3, and miR-21: New regulators of chemokine C receptor 7 expression in mature human dendritic cells.

  2015cited by this paper
• Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1

  2015influential reference
• Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.

  2014cited by this paper
• Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia

  2014cited by this paper
• Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

  2013cited by this paper
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB

  2013cited by this paper
• Cellular origin and pathophysiology of chronic lymphocytic leukemia

  2012cited by this paper
• Targeting B-cell anergy in chronic lymphocytic leukemia.

  2012cited by this paper
• Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia

  2012influential reference
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia

  2012cited by this paper
• An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development

  2012cited by this paper
• Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.

  2012cited by this paper
• The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.

  2012cited by this paper
• The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

  2011cited by this paper
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia

  2007cited by this paper
• Anti‐CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia

  2006influential reference
• Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression

  2006cited by this paper
• Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function

  2006cited by this paper
• Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function.

  2006cited by this paper
• Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry.

  2005cited by this paper
• miR-15 and miR-16 induce apoptosis by targeting BCL2.

  2005cited by this paper
• Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

  2004cited by this paper
• Endothelin-1–Dependent Nuclear Factor of Activated T Lymphocyte Signaling Associates With Transcriptional Coactivator p300 in the Activation of the B Cell Leukemia-2 Promoter in Cardiac Myocytes

  2004cited by this paper
• Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells

  2004influential reference
• Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells.

  2004cited by this paper
• The activities of cyclin D1 that drive tumorigenesis.

  2004cited by this paper
• Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development

  2003cited by this paper
• Partners in transcription: NFAT and AP-1

  2001cited by this paper
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• SYK Is Upstream of Phosphoinositide 3-Kinase in B Cell Receptor Signaling*

  1999cited by this paper
• Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)

  1999cited by this paper
• The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.

  1999cited by this paper
• The role of cell cycle‐mediated events in Alzheimer's disease

  1999cited by this paper
• Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.

  1997cited by this paper
• Transcription factors of the NFAT family: regulation and function.

  1997cited by this paper
• Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane.

  1994cited by this paper
• bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.

  1993cited by this paper
• Genomic hypomethylation in human chronic lymphocytic leukemia.

  1992cited by this paper
• Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

  1991cited by this paper
• Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia

  1990cited by this paper
• The Upper Tail Probabilities of Spearman's Rho

  1975cited by this paper

• Epigenetic therapy for leukemias: a comprehensive review from biological markers to practice.

  2025cites this paper
• Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy

  2024cites this paper
• CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies.

  2024cites this paper
• The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review

  2024cites this paper
• The role of aberrant DNA methylation in cancer initiation and clinical impacts

  2024cites this paper
• The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

  2023cites this paper
• The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies.

  2022cites this paper
• Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool

  2022cites this paper
• Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis

  2022cites this paper
• Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target

  2021cites this paper
• Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies

  2021influential citation
• Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

  2021cites this paper
• Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway

  2021cites this paper
• Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody

  2021cites this paper
• B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells

  2021cites this paper
• Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia

  2021cites this paper
• CCR7 in Blood Cancers – Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target

  2021cites this paper
• The proliferative history shapes the DNA methylome of B-cell 3 tumors and predicts clinical outcome 4 5

  2020cites this paper
• Cold stress promotes IL-33 expression in intestinal epithelial cells to facilitate food allergy development.

  2020cites this paper
• The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

  2020cites this paper
• Novel genes exhibiting DNA methylation alterations in Korean patients with chronic lymphocytic leukaemia: a methyl-CpG-binding domain sequencing study

  2020cites this paper
• Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis

  2020cites this paper
• Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy.

  2020cites this paper
• Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

  2020cites this paper
• TLSurv: Integrating Multi-Omics Data by Multi-Stage Transfer Learning for Cancer Survival Prediction

  2020cites this paper
• Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia

  2019cites this paper
• From Biology to Therapy: The CLL Success Story

  2019cites this paper
• Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives

  2019cites this paper
• Genes Located on 18q23 Are Epigenetic Markers and Have Prognostic Significance for Patients with Head and Neck Cancer

  2019cites this paper
• DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

  2019cites this paper
• Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics

  2019cites this paper
• Epigenetics: Strategies for Prevention Research

  2019cites this paper
• The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia

  2018cites this paper
• Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways

  2018cites this paper
• B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.

  2018cites this paper